Methods: We tested the in vitro susceptibility of VT-1129, VT-1161 and azoles by CLSI broth microdilution (M27-A3) against 31 mucosal Candida strains obtained from patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. We determined the 24-hour minimum inhibitory concentration (MIC) at which 50% of strains were inhibited (MIC50).
Results: Strains tested were C. albicans (20), C. glabrata (6) and 1 each of C. parapsilosis, C. krusei, C. dubliniensis, C. utilis and C. nivariensis; they were recovered from oral (21), vaginal (4), stool (3), esophageal (2) and duodenal (1) cultures. 14 strains were not susceptible to fluconazole based on CLSI breakpoints (MIC equal or
Conclusion: VT-1129 and VT-1161 have in vitro activity against mucosal Candida strains from CMC patients, including azole-resistant strains. Their efficacy in mice and patients with CMC merits investigation.
J. V. Desai,
M. Natarajan, None
C. Henderson, None
A. M. Zelazny, None
W. J. Hoekstra, Viamet: Employee and VP, Chemistry , Salary
R. J. Schotzinger, Viamet Pharmaceuticals, Inc.: President and CEO , Salary
E. P. Garvey, Viamet Pharmaceuticals, Inc: Director of Infectious Disease Biology , Salary
M. S. Lionakis, None